ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
133.009,78
1,08%
S&P 500
5.745,37
0,40%
US Dollar vs BRL
5,4408
0,05%
Bitcoin
65.520,02
0,52%
Brent Oil
71,245
0,42%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Apollomics Inc (APLM)

  7. Apollomics Inc (APLM) Notícias

APLM

Apollomics (APLM)

Apollomics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:APLM
DataHoraFonteTítuloCódigoCompanhia
13/08/202411:50AllPennyStocks.comBiotech Sees Massive Buying Pressure Following Phase 2 Preliminary DataNASDAQ:APLMApollomics Inc
04/06/202409:00GlobeNewswire Inc.Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:APLMApollomics Inc
29/05/202409:00GlobeNewswire Inc.Apollomics Announces Presentation at the 2024 BIO International ConventionNASDAQ:APLMApollomics Inc
08/05/202417:05GlobeNewswire Inc.Apollomics Announces Private Placement Financing and Addition to Board of DirectorsNASDAQ:APLMApollomics Inc
25/04/202409:30GlobeNewswire Inc.Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneNASDAQ:APLMApollomics Inc
10/04/202408:00GlobeNewswire Inc.Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:APLMApollomics Inc
02/04/202409:00GlobeNewswire Inc.Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:APLMApollomics Inc
28/03/202408:00GlobeNewswire Inc.Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial ResultsNASDAQ:APLMApollomics Inc
26/03/202409:00GlobeNewswire Inc.Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024NASDAQ:APLMApollomics Inc
04/03/202409:00GlobeNewswire Inc.Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerNASDAQ:APLMApollomics Inc
07/02/202409:00GlobeNewswire Inc.Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:APLMApollomics Inc
19/01/202418:15GlobeNewswire Inc.Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:APLMApollomics Inc
17/01/202418:30GlobeNewswire Inc.Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology ConferenceNASDAQ:APLMApollomics Inc
03/01/202409:00GlobeNewswire Inc.Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaNASDAQ:APLMApollomics Inc
02/01/202418:30GlobeNewswire Inc.Apollomics to Present at the 2024 Biotech ShowcaseNASDAQ:APLMApollomics Inc
04/12/202309:00GlobeNewswire Inc.Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping MutationNASDAQ:APLMApollomics Inc
29/11/202309:30GlobeNewswire Inc.Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:APLMApollomics Inc
28/11/202309:00GlobeNewswire Inc.Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)NASDAQ:APLMApollomics Inc
16/11/202310:30GlobeNewswire Inc.Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung CancerNASDAQ:APLMApollomics Inc
31/10/202309:30GlobeNewswire Inc.Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET DysregulationNASDAQ:APLMApollomics Inc
26/10/202309:50GlobeNewswire Inc.Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET FusionNASDAQ:APLMApollomics Inc
23/10/202309:30GlobeNewswire Inc.Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%NASDAQ:APLMApollomics Inc
16/10/202319:55GlobeNewswire Inc.Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023NASDAQ:APLMApollomics Inc
28/09/202317:17GlobeNewswire Inc.Apollomics Reports First Half 2023 Financial Results and Provides Corporate UpdateNASDAQ:APLMApollomics Inc
06/09/202308:00GlobeNewswire Inc.Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:APLMApollomics Inc
11/04/202309:30GlobeNewswire Inc.Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller SymposiumNASDAQ:APLMApollomics Inc
10/04/202310:01Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:APLMApollomics Inc
31/03/202317:01Edgar (US Regulatory)Annual Report (10-k)NASDAQ:APLMApollomics Inc
31/03/202308:40PR Newswire (US)Qiming Venture Partners Welcomes Apollomics' Successful IPO on NasdaqNASDAQ:APLMApollomics Inc
30/03/202309:00GlobeNewswire Inc.Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on NasdaqNASDAQ:APLMApollomics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:APLM

Seu Histórico Recente

BOV
PRIO3
PETRORIO ON
BOV
IBOV
Índice Bovespa
BOV
PDGR3
PDG REALT ON
BOV
CBEE3
AMPLA ENERG ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados